+Compare
GENE
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
14.83M

GENE Genetic Technologies Ltd Forecast, Technical & Fundamental Analysis

a company which engages in the business of genetic testing services

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for GENE with price predictions
08:00 PM EDT Sep 28, 2023

Momentum Indicator for GENE turns negative, indicating new downward trend

GENE saw its Momentum Indicator move below the 0 level on September 25, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned negative. In of the 96 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for GENE moved out of overbought territory on September 19, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 15 similar instances where the indicator moved out of overbought territory. In of the 15 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for GENE turned negative on September 26, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .

GENE moved below its 50-day moving average on September 28, 2023 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GENE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The 10-day moving average for GENE crossed bullishly above the 50-day moving average on September 13, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GENE advanced for three days, in of 198 cases, the price rose further within the following month. The odds of a continued upward trend are .

GENE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 58 cases where GENE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.070) is normal, around the industry mean (24.898). P/E Ratio (0.000) is within average values for comparable stocks, (79.320). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (6.382). Dividend Yield (0.000) settles around the average of (0.019) among similar stocks. P/S Ratio (2.337) is also within normal values, averaging (58.126).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. GENE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GENE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Intuitive Surgical (NASDAQ:ISRG), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW), IQVIA Holdings (NYSE:IQV), Align Technology (NASDAQ:ALGN), Illumina (NASDAQ:ILMN), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH).

Industry description

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

Market Cap

The average market capitalization across the Medical Specialties Industry is 6.32B. The market cap for tickers in the group ranges from 27 to 3.82T. MKYSF holds the highest valuation in this group at 3.82T. The lowest valued company is FOGCF at 27.

High and low price notable news

The average weekly price growth across all stocks in the Medical Specialties Industry was 4%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was -6%. FEMY experienced the highest price growth at 868%, while AVGR experienced the biggest fall at -45%.

Volume

The average weekly volume growth across all stocks in the Medical Specialties Industry was 137%. For the same stocks of the Industry, the average monthly volume growth was 32% and the average quarterly volume growth was 149%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 71
Price Growth Rating: 67
SMR Rating: 84
Profit Risk Rating: 88
Seasonality Score: -20 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published General Information

General Information

a company which engages in the business of genetic testing services

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Biotechnology
Address
60-66 Hanover Street
Phone
+61 384127000
Employees
60
Web
https://www.gtglabs.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KINS1.790.18
+11.18%
Kingstone Companies
RIVN24.291.21
+5.24%
Rivian Automotive
CBD0.670.02
+3.14%
Companhia Brasileira de Distribuicao
YALA5.240.12
+2.34%
Yalla Group Limited
BPMC50.22-0.85
-1.66%
Blueprint Medicines Corp

GENE and

Correlation & Price change

A.I.dvisor indicates that over the last year, GENE has been loosely correlated with RSLS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GENE jumps, then RSLS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GENE
1D Price
Change %
GENE100%
-1.09%
RSLS - GENE
46%
Loosely correlated
-23.18%
HSCS - GENE
36%
Loosely correlated
+0.85%
PSNL - GENE
35%
Loosely correlated
+3.36%
BNGO - GENE
32%
Poorly correlated
+4.48%
AXNX - GENE
32%
Poorly correlated
-1.54%
More

Groups containing GENE

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GENE
1D Price
Change %
GENE100%
-1.09%
biotechnology
(undefined stocks)
14%
Poorly correlated
-2.80%
drugs
(undefined stocks)
13%
Poorly correlated
-2.65%
genes
(undefined stocks)
12%
Poorly correlated
-0.82%
Medical Specialties
(undefined stocks)
9%
Poorly correlated
+2.54%
Medical Specialties
(undefined stocks)
9%
Poorly correlated
+2.54%
More